Singapore markets closed

MYND Lifesciencs Inc. (MYNDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.17540.0000 (0.00%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.1754
Open0.1754
BidN/A x N/A
AskN/A x N/A
Day's range0.1754 - 0.1754
52-week range0.1610 - 1.1000
Volume3,000
Avg. volume544
Market cap8.056M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • CNW Group

    MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

    MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the "Agreement") with the University of British Columbia ("UBC") focussing on Novel Therapies for Neurological Diseases.

  • CNW Group

    MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other Dementias

    Further to news release of October 27, 2021, MYND Life Sciences Inc. ("MYND") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has successfully closed on the previously announced transaction to acquire the right, title and interest in and to the intellectual property rights for the use of psychedelics to treat Dementia (the "Acquired Assets") from Cava Healthcare Inc. ("Cava"), a life sciences company based in Surrey, British Columbia. The acquisition includes all future worldwide rights relat

  • CNW Group

    MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

    MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: "A Method of Immune Modulation by Modulating a Specific Gene."